Treatment of Depression in Adults
|Depression||Drug: Escitalopram Behavioral: Interpersonal Psychotherapy Other: Escitalopram plus IPT||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Depression: The Search for Treatment-Relevant Phenotypes|
- Hamilton Rating Scale for Depression score [ Time Frame: Measured at Months 8 and 14 ]
- Treatment-relevant phenotypes of depression [ Time Frame: Measured at Months 8 and 14 ]
|Study Start Date:||May 2003|
|Study Completion Date:||October 2007|
|Primary Completion Date:||October 2007 (Final data collection date for primary outcome measure)|
Behavioral: Interpersonal Psychotherapy
Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.
Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
Escitalopram plus IPT
Other: Escitalopram plus IPT
Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
Major depression is a serious condition that can have devastating functional consequences. Although numerous depression studies have been conducted, understanding of how best to achieve long-term recovery remains limited. This study will assess the mood, personality, pharamcokinetic and genetic characteristics of depressed participants to determine the effects of these features on treatment response.
This study will be conducted at two international treatment sites, including the University of Pittsburgh and the University of Pisa, Italy. Participants will be randomly assigned to receive either interpersonal psychotherapy (IPT) or escitalopram pharmacotherapy for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months; those who do not will have the second treatment added to their regimen until remission occurs. Clinical evaluations and questionnaires will be used to assess participants.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00073697
|United States, Pennsylvania|
|Western Psychiatric Institute and Clinic - Depression Prevention Program|
|Pittsburgh, Pennsylvania, United States, 15213|
|The University of Pisa|
|Principal Investigator:||Ellen Frank||University of Pittsburgh|